• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Specialty Pharmacy Drives 3.8% Increase in Drug Prices

by Jasmine Pennic 01/31/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Vizient, Inc., a leading healthcare performance improvement company, has released its latest Pharmacy Market Outlook, projecting a 3.8% growth in drug price inflation.

– The increase is the highest since July 2019 and is attributed in part to the expanding realm of specialty pharmacy, notably the increased utilization of weight loss drugs. The report also highlights the anticipated rise in provider spending due to the expansion of gene therapies.

Price of Specialty Medications

The majority of the top 15 medications in spend among Vizient pharmacy program participants fall under specialty pharmaceuticals, addressing high-cost, complex, or chronic conditions such as cancer, infectious diseases, autoimmune disorders, and pulmonary conditions. The report indicates a projected 4.18% increase in the price of specialty medications, driven by the approval of 42 novel specialty drugs in 2023, with an anticipated record number of approvals in 2024.

Increased Provider Spending

The two major contributors to the surge in provider spending identified in the report are weight loss drugs and gene therapy:

– Weight Loss Drugs: The spending and utilization of glucagon-like peptide receptor 1 agonists (GLP-1s), primarily used for treating type 2 diabetes and obesity, have witnessed a significant uptick. Semaglutide, a prominent GLP-1 agonist, has climbed to the No. 5 spot in total Vizient customer spend, a noteworthy rise from its No.18 position a year ago. Competition in this space, exemplified by the introduction of tirzepatide (Zepbound™) for weight loss in December 2023, is expected to impact bariatric surgery volumes, with a forecasted 4% reduction by 2033.

– Gene Therapy: The report underscores the rapid growth of gene therapy, a field involving the modification of gene expression for therapeutic purposes. A single dose of gene therapy can exceed $2 million. With 11 approved gene therapy products currently available, Vizient is tracking over 170 gene and cellular therapies in the pipeline. Despite their potential for revolutionizing disease prevention and treatment, challenges such as high costs, reimbursement coding, and ultra-low-temperature storage requirements need to be addressed.

Biosimilars Growth

The report also anticipates the growing market share of biosimilars, accounting for 24.93% of purchasing volume for originator products. While biosimilars are expected to increase in price by only 0.55%, Humira® remains dominant, representing 99% of Vizient customer adalimumab purchases through September 2023.

Remdesivir

Notably, Remdesivir, an anti-viral agent used in COVID-19 treatment, has dropped out of the Vizient overall top 15 medications but remains the top spend agent in the acute care segment.

Pharmacy Market Outlook Report/Background

The projections presented in the Pharmacy Market Outlook are based on total Vizient Pharmacy program participant spending from October 2022 through September 2023, with price change estimates projected for July 1, 2024, through June 30, 2025. The report underscores the importance of proactive management of pharmacy expenditures and adaptation to emerging trends for healthcare institutions to navigate the evolving landscape successfully.

“Many hospitals around the country experienced a challenging 2023, including drug shortages and rising drug costs,” acknowledged Carina Dolan, Associate Vice President of Clinical Oncology, Pharmacoeconomics, and Market Insights at Vizient. “Managing pharmacy expenditures and strengthening the supply chain is more important than ever.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |